These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17916760)

  • 1. Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices.
    Sturton RG; Trifilieff A; Nicholson AG; Barnes PJ
    J Pharmacol Exp Ther; 2008 Jan; 324(1):270-5. PubMed ID: 17916760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.
    Battram C; Charlton SJ; Cuenoud B; Dowling MR; Fairhurst RA; Farr D; Fozard JR; Leighton-Davies JR; Lewis CA; McEvoy L; Turner RJ; Trifilieff A
    J Pharmacol Exp Ther; 2006 May; 317(2):762-70. PubMed ID: 16434564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi.
    Naline E; Trifilieff A; Fairhurst RA; Advenier C; Molimard M
    Eur Respir J; 2007 Mar; 29(3):575-81. PubMed ID: 17135231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.
    Aparici M; Gómez-Angelats M; Vilella D; Otal R; Carcasona C; Viñals M; Ramos I; Gavaldà A; De Alba J; Gras J; Cortijo J; Morcillo E; Puig C; Ryder H; Beleta J; Miralpeix M
    J Pharmacol Exp Ther; 2012 Aug; 342(2):497-509. PubMed ID: 22588259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formoterol and salmeterol induce a similar degree of β2-adrenoceptor tolerance in human small airways but via different mechanisms.
    Cooper PR; Kurten RC; Zhang J; Nicholls DJ; Dainty IA; Panettieri RA
    Br J Pharmacol; 2011 Jun; 163(3):521-32. PubMed ID: 21306583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and binding characteristics of long-acting beta 2-agonists in lung and heart.
    Roux FJ; Grandordy B; Douglas JS
    Am J Respir Crit Care Med; 1996 May; 153(5):1489-95. PubMed ID: 8630591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of action of inhaled vs. Intravenous beta(2)-adrenoceptor agonists in an anaesthetized guinea-pig model.
    Mohammed SP; Taylor CV; Weyman-Jones CB; Mather ME; Vendy K; Dougall IG; Young A
    Pulm Pharmacol Ther; 2000; 13(6):287-92. PubMed ID: 11061983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
    Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
    Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.
    Ryall JG; Sillence MN; Lynch GS
    Br J Pharmacol; 2006 Mar; 147(6):587-95. PubMed ID: 16432501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Indacaterol--a new hope for maximising bronchodilation?].
    Mihălţan F
    Pneumologia; 2011; 60(1):21-5. PubMed ID: 21548196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus.
    Naline E; Zhang Y; Qian Y; Mairon N; Anderson GP; Grandordy B; Advenier C
    Eur Respir J; 1994 May; 7(5):914-20. PubMed ID: 7914176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.
    Kornmann O; Dahl R; Centanni S; Dogra A; Owen R; Lassen C; Kramer B;
    Eur Respir J; 2011 Feb; 37(2):273-9. PubMed ID: 20693243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?
    Lombardi D; Cuenoud B; Krämer SD
    Eur J Pharm Sci; 2009 Dec; 38(5):533-47. PubMed ID: 19819331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol.
    Aziz I; Lipworth BJ
    J Allergy Clin Immunol; 1999 May; 103(5 Pt 1):816-22. PubMed ID: 10329815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists.
    Lindén A; Rabe KF; Löfdahl CG
    Lung; 1996; 174(1):1-22. PubMed ID: 8746998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase.
    Teschemacher A; Lemoine H
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1084-92. PubMed ID: 10027845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone.
    Balint B; Watz H; Amos C; Owen R; Higgins M; Kramer B;
    Int J Chron Obstruct Pulmon Dis; 2010 Sep; 5():311-8. PubMed ID: 20856830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.
    Baur F; Beattie D; Beer D; Bentley D; Bradley M; Bruce I; Charlton SJ; Cuenoud B; Ernst R; Fairhurst RA; Faller B; Farr D; Keller T; Fozard JR; Fullerton J; Garman S; Hatto J; Hayden C; He H; Howes C; Janus D; Jiang Z; Lewis C; Loeuillet-Ritzler F; Moser H; Reilly J; Steward A; Sykes D; Tedaldi L; Trifilieff A; Tweed M; Watson S; Wissler E; Wyss D
    J Med Chem; 2010 May; 53(9):3675-84. PubMed ID: 20402514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological similarities and differences between beta2-agonists.
    Lötvall J
    Respir Med; 2001 Aug; 95 Suppl B():S7-11. PubMed ID: 11534896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.